Sponsors

Lead Sponsor

Vical

Treatment - If you take part in this trial you will be treated for about 10 weeks. You will receive an injection of Allovectin-7® by needle, directly into one or more selected tumors once a week for the first six weeks. The injections may be given in a doctor's office. During a four-week observation period, your disease will be measured to see if the treatment is working. This will be done by general physical exams and scans (such as X-ray scans). Patients who show no sign of disease progression may be offered an option to repeat this treatment course.

Related studies

RECRUITINGPhase 2

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

NCT02621021 · Melanoma

RECRUITINGPhase 1

Phase II Trial of Allovectin-7® for Metastatic Melanoma

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Sponsors

Related studies

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

A Study of DXC014 in Patients With Advanced Solid Tumors.

Familial Investigations of Childhood Cancer Predisposition

Dabrafenib and/or Trametinib Rollover Study

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Trial snapshot

Condition

Locations shown

For caregivers